摘要目的 探讨孟鲁司特钠在稳定期慢性阻塞性肺疾病(COPD)患者中的应用价值.方法 选择辽宁省金秋医院2015年12月至2016年12月门诊就诊的64例稳定期COPD患者,按照随机数字表法分为观察组及对照组,各32例.两组均进行常规治疗,包括止咳、祛痰、氧疗、戒烟、康复治疗、规律使用长效支气管舒张剂等,在此基础上,治疗组加用孟鲁司特钠.治疗12周后,对患者进行治疗前后的气道通气改善和生存质量的评估,并记录两组急性加重例数以及药物不良反应.结果 治疗后两组肺功能及生活质量均有改善,但治疗后观察组FEV1、FVC及FEV1实/FEV1预明显高于对照组,差异均有统计学意义(t=2.49、1.77、1.85,均P＜0.05).治疗后观察组患者6 min步行距离长于对照组,Borg评分低于对照组,差异均有统计学意义(t=1.83、6.66,均P＜0.05).治疗后SGRQ问卷总分观察组低于对照组,差异有统计学意义[(51.15±3.14)分比(54.83 ±4.03)分,(t=3.94,P＜0.01)].结论 孟鲁司特钠可有效改善稳定期COPD患者肺功能和生活质量,且安全性高.

abstractsObjective To investigate the application value of montelukast in patients with stable chronic obstructive pulmonary disease (COPD).Methods 64 patients with stable COPD in Jinqiu Hospital of Liaoning Province from December 2015 to December 2016 were randomly divided into observation group and control group according to the digital table,32 cases in each group.The two groups were given routine treatment,including cough,phlegm,oxygen therapy,smoking cessation,rehabilitation treatment,regular use of long-acting bronchodilators,on this basis,the observation group was treated with montelukast sodium.After 12 weeks of treatment,the patients were assessed for airway improvement and quality of life before and after treatment,and recorded the two groups of acute exacerbation and adverse drug reactions.Results The two groups had improved lung function and quality of life after treatment,but after treatment,the FEV1,FVC and FEV1 actual/FEV1 prediction of the observation group were significantly higher than those of the control group,the differences were statistically significant (t =2.49,1.77,1.85 all P ＜ 0.05).After treatment,the 6 minutes walking distance of the observation group was longer than that of the control group,Borg score of the observation group was lower than that of the control group,the differences were statistically significant (t =1.83,6.66,all P ＜0.05).After treatment,the SGRQ score in the observation group was lower than that of the control group,the difference was statistically significant[(51.15 ± 3.14)points vs.(54.83 ± 4.03)points,t =3.94,P ＜ 0.01].Conclusion Montelukast can effectively improve the stability of COPD pulmonary function and quality of life,and with high safety.